Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Novavax, Inc.

Events at Novavax

We’re making a difference in the health of people around the world by producing next generation vaccines that are accessible to more people. We stand strong against infectious diseases and viral threats—our science grounds us, our technology pushes us forward, our commitment inspires us to achieve our hopes. We do this work for the greater health of people everywhere. It’s more than our job. It’s our passion.

Our Novavax Social Community Guidelines: https://www.novavax.com/social-media-community-guidelines

Bill & Melinda Gates Foundation

Coalition for Epidemic Preparedness Innovations

Government of United States of America

Innovations Kapital

SK Bioscience

RA Capital Management

Novavax

Join Lucie Kutikova, PhD, Senior Director, Real World Evidence, Head of Europe & Middle East, Jonas Lundkvist, Senior Director, Real World Evidence, Europe region, and Chengbin Wang, Senior Director, Safety Epidemiology and Benefit Risk, as they present at #ISPOREurope 2023. 
 
Learn more: https://lnkd.in/dviJMvMS

Join Matt Rousculp, Vice President, Real World Evidence, as he presents at #ISPOREurope 2023 on November 13 from 10:30-13:30 UTC. 
 
Learn more: https://lnkd.in/dviJMvMS  
 
#ISPOREurope #NovavaxEurope #Announcement

Novavax is attending ISPOR—The Professional Society for Health Economics and Outcomes Research Europe 2023 on November 12-15 in Copenhagen, Denmark! We look forward to hearing from experts on the role of health economics and outcomes research (HEOR) and how it shapes policy. 
 
Learn more: https://lnkd.in/dviJMvMS  
 
#ISPOREurope #NovavaxEurope #Announcement

Happy #Diwali from all of us at Novavax!✨ We hope this festival of lights fills your life with joy, love, and prosperity.

On this #Veteran’sDay, Novavax honors our nation’s Veteran’s, and the outstanding support Blue Star Families provides to them, every day of the year! #grateful

Novavax is pleased to announce new publications in Scientific Reports and Frontiers in Drug Delivery. View papers here: https://lnkd.in/gUqYnxmx

Nathalie S., Threat Intel Analyst, Information Security, shares the preparation her military service provided that she now utilizes in her role at Novavax.

Novavax is attending the 39th Pulmonology Congress in Algarve, Portugal on November 9-11! We look forward to learning alongside leaders in pulmonology.  
 
Learn more about Novavax Portugal: https://novavax.pt/ 
 
#NovavaxEurope #NovavaxPortugal #Announcement

Don't miss out on the poster presentation from Matt Rousculp, Vice President, Real World Evidence, at the Asian Vaccine Conference!  
 
Learn more: https://asianvaccine.com/

This week, Anthony Q. Singleton, Director of IT End User Services, shares the parallels of his service in the armed forces, and current position at Novavax amid an ongoing worldwide health crisis.

COM:NOVAVAX

Novavax, Inc.

Last Close

9.01

12/11 20:19

Market Cap

1.68B

Beta: -

Volume Today

8.61M

Avg: -

People Not Available